TY - JOUR
T1 - Monitoring vitamin B12 in women treated with metformin for primary prevention of breast cancer and age-related chronic diseases
AU - Mastroianni, Antonio
AU - Ciniselli, Chiara Maura
AU - Panella, Rossella
AU - Macciotta, Alessandra
AU - Cavalleri, Adalberto
AU - Venturelli, Elisabetta
AU - Taverna, Francesca
AU - Mazzocchi, Arabella
AU - Bruno, Eleonora
AU - Muti, Paola
AU - Berrino, Franco
AU - Verderio, Paolo
AU - Morelli, Daniele
AU - Pasanisi, Patrizia
PY - 2019/5
Y1 - 2019/5
N2 - Metformin (MET) is currently being used in several trials for cancer prevention or treatment in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of total vitamin B12. In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET, whose participants were characterized by different components of metabolic syndrome, we tested the effect of MET on serum levels of B12, holo transcobalamin II (holo-TC-II), and methylmalonic acid (MMA). The study was conducted on 165 women receiving MET or placebo for three years. Results of the study indicate a significant overall reduction in both serum total B12 and holo-TC-II levels according with MET-treatment. In particular, in the MET group 26 of 81 patients and 10 of the 84 placebo-treated subjects had B12 below the normal threshold (<221 pmol/L) at the end of the study. Considering jointly all B12, Holo-TC-II, and MMA, 13 of the 165 subjects (10 MET and 3 placebo-treated) had at least two deficits in the biochemical parameters at the end of the study, without reporting clinical signs. Although our results do not affect whether women remain in the trial, B12 monitoring for MET-treated individuals should be implemented.
AB - Metformin (MET) is currently being used in several trials for cancer prevention or treatment in non-diabetics. However, long-term MET use in diabetics is associated with lower serum levels of total vitamin B12. In a pilot randomized controlled trial of the Mediterranean diet (MedDiet) and MET, whose participants were characterized by different components of metabolic syndrome, we tested the effect of MET on serum levels of B12, holo transcobalamin II (holo-TC-II), and methylmalonic acid (MMA). The study was conducted on 165 women receiving MET or placebo for three years. Results of the study indicate a significant overall reduction in both serum total B12 and holo-TC-II levels according with MET-treatment. In particular, in the MET group 26 of 81 patients and 10 of the 84 placebo-treated subjects had B12 below the normal threshold (<221 pmol/L) at the end of the study. Considering jointly all B12, Holo-TC-II, and MMA, 13 of the 165 subjects (10 MET and 3 placebo-treated) had at least two deficits in the biochemical parameters at the end of the study, without reporting clinical signs. Although our results do not affect whether women remain in the trial, B12 monitoring for MET-treated individuals should be implemented.
KW - Holotranscobalamin ii
KW - Metformin
KW - Methylmalonic acid
KW - Vitamin B
UR - http://www.scopus.com/inward/record.url?scp=85065754056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065754056&partnerID=8YFLogxK
U2 - 10.3390/nu11051020
DO - 10.3390/nu11051020
M3 - Article
C2 - 31067706
AN - SCOPUS:85065754056
VL - 11
JO - Nutrients
JF - Nutrients
SN - 2072-6643
IS - 5
M1 - 1020
ER -